Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph3 Pembro + BCG High-risk Bladder View
Description: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: IV
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Brain Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Cervical Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph2 Cervical 2L (RaPiDS) View
Description: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028)
Indication:
Cervical Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Colon Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 TSR-042+car-pac vs plac+car-pac endo View
Description: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Esophageal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Nivo+Rucap Ovarian (ATHENA) View
Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Liver Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Liver Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Adj canakinumab NSCLC View
Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph 1 PF-06821497 R/R SCLC, CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph 1 PF-06821497 R/R SCLC, CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Melanoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph 1/2 ASTX727 Lower Risk MDS View
Description: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Nivo+Rucap Ovarian (ATHENA) View
Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View
Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b View
Description: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Nivo+Rucap Ovarian (ATHENA) View
Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph 1 PF-06821497 R/R SCLC, CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Rectal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Renal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph 1 PF-06821497 R/R SCLC, CRPC & FL View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Biomarker Advcd Uro Cncer and FGFR Aber View
Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: IV